Quantum Private Wealth LLC Has $1.13 Million Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Quantum Private Wealth LLC raised its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 11.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 639,520 shares of the company’s stock after buying an additional 64,140 shares during the quarter. Quantum Private Wealth LLC owned about 0.34% of Taysha Gene Therapies worth $1,132,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Capital Investment Advisors LLC bought a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $32,000. AQR Capital Management LLC bought a new stake in shares of Taysha Gene Therapies during the second quarter valued at approximately $38,000. Howard Capital Management Inc. bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $25,000. Maven Securities LTD bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $34,000. Finally, Lee Financial Co bought a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $63,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock traded down $0.07 on Wednesday, reaching $2.51. The company’s stock had a trading volume of 445,227 shares, compared to its average volume of 2,665,923. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The business’s fifty day moving average price is $2.51 and its 200 day moving average price is $2.10. Taysha Gene Therapies, Inc. has a twelve month low of $0.50 and a twelve month high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.39 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on TSHA shares. Needham & Company LLC restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, April 11th. Chardan Capital boosted their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, March 21st. Canaccord Genuity Group reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $6.88.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.